Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Organ Preservation in Rectal Cancer by Dose Escalated MR Guided Adaptive Radiotherapy

NCT07337876 is registered in ClinicalTrials.gov with University Hospital Tuebingen as lead sponsor.

NCT NCT07337876
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07337876 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Organ Preservation in Rectal Cancer by Dose Escalated MR Guided Adaptive Radiotherapy
Lead sponsor
University Hospital Tuebingen
Phase
Phase 2
Overall status
Recruiting
Start date
January 7, 2026
Completion date
January 31, 2029
Enrollment
100 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

rectal cancer